Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

  • Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NGT5TVlHfW6ldHnvckBCe3OjeR?= NFnwcVcxNjFvM{Cg{txO M4XiS|Q5KGh? NEDsNWFqdmS3Y3XzJGlESU1vMTDlfJBz\XO|aX;uJI9vKGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdA>? NYPwXZFmOjZ3MUOxO|I>
H460 NG[zUmlHfW6ldHnvckBCe3OjeR?= MkS4NE4yNTNyIN88US=> M1nJeVQ5KGh? MYrpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> NHvscVYzPjVzM{G3Ni=>
HKESC-2 M3nnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTPNlDDqM7:TR?= M1HSblQ5yqCqwrC= Mn3Yd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh NV[wXYNnOjZ2N{S2PVM>
CaES-17 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWyNOKh|ryP NVO2fHF1PDkEoHlCpC=> NFHXfnB{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? MnvKNlY1PzR4OUO=
HKESC-2 MlPRRZBweHSxc3nzJGF{e2G7 MYWyNOKh|ryP NFfsSYE1QMLiaNMg NYTLZVFVemWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>? MXOyOlQ4PDZ7Mx?=
CaES-17 NWfReWQ6SXCxcITvd4l{KEG|c3H5 NF73bmwzOMLizszN NYWxUJNUPDkEoHlCpC=> MlPPdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MXuyOlQ4PDZ7Mx?=
A549 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjLbYdlPS1zNkCg{txO Mom4OFjDqGkEoB?= M3v0N2ROW09? MnjiTWM2OD1zNkOuOEDPxE1? NEfRXo8zPjR4NE[0Ny=>
HCC827 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uxblUuOTZyIN88US=> MniwOFjDqGkEoB?= NIKzXo9FVVOR NF:2OoFKSzVyPU[5MlIh|ryP MYeyOlQ3PDZ2Mx?=
A549 MVTBdI9xfG:|aYOgRZN{[Xl? MlO3PFAhyrWP NGO4W5Q1QMLiaNMg NHfaOVBFVVOR M1vyUolv\HWlZYOgZZBweHSxc3nz NYHJ[2ZvOjZ2NkS2OFM>
HCC827 NVO3TFhXSXCxcITvd4l{KEG|c3H5 MX64NEDDvU1? M1jIPVQ5yqCqwrC= NVj1c29jTE2VTx?= NX\YTZc4cW6mdXPld{BieG:ydH;zbZM> NEj5TZozPjR4NE[0Ny=>
SGC-7901/DDP MULGeY5kfGmxbjDBd5NigQ>? M1HnRVExyqEEtV2= MUmyOEBp MnzlbY5pcWKrdIOgZ5lkdG:xeInn[Y5ie2VvMjDhcoQhWC2pbInjc5Bzd3SnaX6g[ZhxemW|c3nvci=> M2fjcVI3PDB5NkWz
SGC-7901  M17hcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXmVpEzPMLiaNMg M4fvTmlEPTB;MUG1MlA5KM7:TR?= M1\kb|I3PDB5NkWz
SGC-7901/DDP NInVcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjGeoIzPMLiaNMg MV3JR|UxRTN3LkS1JO69VQ>? M2HqcFI3PDB5NkWz
SGC-7901/DDP MWnBdI9xfG:|aYOgRZN{[Xl? M36xWFExyqEEtV2= M4\tWVI1KGh? MkXHbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=> M3TjVVI3PDB5NkWz
SGC-7901/DDP NXzo[2pqTnWwY4Tpc44hSXO|YYm= MnniNVDDqML3TR?= M3L5TVI1KGh? MmjCbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gVE1odHmlb4Dyc5RmcW5idHjyc5VocCCkbH;jb4lv\yCHUEKsJIFv\CCrbnHjeIl3[XSrbnegVGtCKGGwZDDDVmVDyqB? NX;PTXBmOjZ2MEe2OVM>
SGC-7901/DDP M4L3UmZ2dmO2aX;uJGF{e2G7 NUO0e48{OTEEoNM1US=> M1K0WVI1KGh? NFOwfnlk[XW|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4> NITrbZEzPjRyN{[1Ny=>
H357 M2jh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq5[4FoPy53L{GwJO69VQ>? MnSwOFghcA>? NEnBc4JFVVOR MWDpcohq[mm2czDj[YxtKGe{b4f0bOKh[2:vYnnu[YQhf2m2aDDTZYJ2fG:lbHH4 Ml;qNlYxODl6N{S=
TAF NILqW5RHfW6ldHnvckBCe3OjeR?= M17WWlExyqEEtV2= NVHnTGJLPyCm NITTdWhi\m[nY4TzJHRCTnNiYXTo[ZNqfmVicILvdIVzfGmncx?= MlTPNlU6QDdzMke=
TAF NVvtXnFJTnWwY4Tpc44hSXO|YYm= NHXpVXkyOMLiwsXN M3nMXVMxNTF{MDDtbY4> MY\wc49zdHliYX\m[YN1eyCmQXv0JJBpd3OyaH;yfYxifGmxbjDjc45{\XG3ZX70JJRwKEWJRjDzbYdv[Wyrbne= M4OweFI2QTh5MUK3
TAF MnPnSpVv[3Srb36gRZN{[Xl? NHPOToUyOMLiwsXN M3nMTlQ5KGh? NHru[5dqdmO{ZXHz[ZMhTUeIUjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MkPmNlU6QDdzMke=
PANC-1 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[2NlAwPjBxMUCwJO69VQ>? NV23Z5RDOjRxNEivO|IhcA>? MlXlbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NF;VO|IzPTl5M{C2Ni=>
PANC-1 MYXGeY5kfGmxbjDBd5NigQ>? NHLlRZQzOC94MD:xNFAh|ryP M2nlS|I1KGh? NUX6THUy[XS2ZX71ZZR{KGOnbHygbY53[XOrb36gZY5lKG2rZ4LheIlwdiCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi Mm\BNlU6PzNyNkK=
HeLa  NH;vTJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDiNo9xOjEEoN88UeKh Mlu0NlTDqGh? MXPlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? MlvwNlU4PzB2MkO=
SACC-83 NGDEeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF33SpYzOMLizszNxsA> M{WyPFI1yqCq MUHlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? NFywUVczPTd5MESyNy=>
HeLa  M4T1eWFxd3C2b4Ppd{BCe3OjeR?= NY\PSGh7OjEEoN88UeKh NHXCdnIzPMLiaB?= NXnKO4JL\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? M3XZNlI2PzdyNEKz
SACC-83 M3:0RmFxd3C2b4Ppd{BCe3OjeR?= NWrmc4J3OjEEoN88UeKh NUnXUYNTOjUEoHi= NGrnNmlmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ MWKyOVc4ODR{Mx?=
HeLa  MXrGeY5kfGmxbjDBd5NigQ>? MkPqNlAwPDBxOECg{txO MlrvNlTDqGh? MV71dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> M4LSZ|I2PzdyNEKz
SACC-83 MlSzSpVv[3Srb36gRZN{[Xl? MmfaNlAwPDBxOECg{txO NUS5fnB4OjUEoHi= NYn3clBFfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? MXmyOVc4ODR{Mx?=
HLCZ01 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f1ZVDjiJN4MNMgxtVO NGnxcnk1QCCq M2\xe2ROW09? M1;HdYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M4rORlI2PzJ2OEm5
HLCZ01 NYHKXnh4TnWwY4Tpc44hSXO|YYm= NUT3XYZUPDEEoN88US=> NYfyTmxTOjRiaB?= NV3z[I16TE2VTx?= M3\qb4lv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> NFjnfGkzPTd{NEi5PS=>
HLCZ01 NELpVnNCeG:ydH;zbZMhSXO|YYm= NI\0Npc1OMLizszN NGf3e5IzPCCq MVrEUXNQ NIW1O3ZmdmijbnPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDJSm4u|rF? NXzCcoI{OjV5MkS4PVk>
HLCZ01 MXjGeY5kfGmxbjDBd5NigQ>? MUi0NOKh|ryP MoLPNlQhcA>? NFPwdo1FVVOR NXPwdWFwcW6lcnXhd4V{KFSUQVnMJIV5eHKnc4Ppc44h[2:vYnnu[YQhf2m2aDDJcpRmem[ncn;uMe6y NVL5[WRFOjV5MkS4PVk>
MGC803 NF;6NI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInwTm8xNTZyIN88US=> NIL4SW84OiCq MnPnTWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2= NXH0SXFWOjV5MEGzO|g>
SGC7901 M4HV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmwMVYxKM7:TR?= MYe3NkBp Mnm2TWM2OD12Mz61N-KBkcLz4pEJOU4yOiEQvF2= MnTuNlU4ODF|N{i=
MGC803 MWrGeY5kfGmxbjDBd5NigQ>? M1vSbFQxyqEQvF2= MlO5PE8yPi9{NDDo MWf1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36= MmDnNlU4ODF|N{i=
SGC7901 MnzDSpVv[3Srb36gRZN{[Xl? NVXFPFViPDEEoN88US=> M1zIRVgwOTZxMkSgbC=> MWn1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36= M1rFWlI2PzBzM{e4
MCF-7  M4O5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnxNU8yOCEQvF2= NHKzfHg4OiCq M3vOZ2ROW09? NVPROYdT\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= M3XO[|I2PjZ5NUGw
MDA-MB-231  M1Twd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[zU3UyNzFyIN88US=> MVm3NkBp NXvCOFBzTE2VTx?= MlzZ[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? NXPiWngzOjV4Nke1NVA>
MDA-MB-231 MV7GeY5kfGmxbjDBd5NigQ>? MVKwMVQxKML3TR?= MVy0MVI1KGh? NIDWdYNqdmO{ZXHz[ZMhS0:[LUKgdJJwfGWrbjDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVz M33M[VI2PTh5M{K5
MCF-7 NF;uV2RHfW6ldHnvckBCe3OjeR?= MUiwMVQxKML3TR?= M4P3fFQuOjRiaB?= Mlv1[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? NGH1VoEzPTV6N{OyPS=>
MCF7-MX  M3nDd2Z2dmO2aX;uJGF{e2G7 M1ruN|AuPDBiwsXN MkTOOE0zPCCq NFfQ[ZdmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi M4\ycFI2PTh5M{K5
MDA-MB-231 MY\GeY5kfGmxbjDBd5NigQ>? NGD1[3YxNTRyINM1US=> Mn3EOE0zPCCq MVvzeIlufWyjdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGFDS0d{IIXwJJRwKDRwMkegeIlu\XNidH:gZ49vfHKxbDDs[ZZmdCCkeTCxNkBpyqB? M3fodlI2PTh5M{K5
A2780 M2jtR2Z2dmO2aX;uJGF{e2G7 MnrEOU8yOC9zNTFOwG0> MlTJOFghcA>? NHm5WWFl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFLrd2UzPTR{NEi5PC=>
SKOV3  M1z4S2Z2dmO2aX;uJGF{e2G7 M37wTlUwOTBxMUWg{txO M2j1PFQ5KGh? MoTB[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3nlO|I2PDJ2OEm4
A2780 NYf5[Xd6TnWwY4Tpc44hSXO|YYm= M1vFeFUwOTBxMUWg{txO NFiwbYo1QCCq NYrPfVRW\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= NHy2VW0zPTR{NEi5PC=>
SKOV3  M171e2Z2dmO2aX;uJGF{e2G7 NIDKbFg2NzFyL{G1JO69VQ>? M1PkUFQ5KGh? NWG1b5FC\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= MWGyOVQzPDh7OB?=
A2780 M3\2PWZ2dmO2aX;uJGF{e2G7 MXi1M|ExNzF3IN88US=> M2THUFQ5KGh? Mmnl[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw M{TlVlI2PDJ2OEm4
SKOV3  MY\GeY5kfGmxbjDBd5NigQ>? NWrDUmpRPS9zMD:xOUDPxE1? NEfsWG01QCCq MYLk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? M{DBZVI2PDJ2OEm4
A2780 M2\TTWZ2dmO2aX;uJGF{e2G7 M4WyUlUwOTBxMUWg{txO MYGxJIg> NGTHVI9qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4LaN|I2PDJ2OEm4
SKOV3  M4i0bGZ2dmO2aX;uJGF{e2G7 NVfmS2JRPS9zMD:xOUDPxE1? NIXDTIIyKGh? M4TDeIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MomyNlU1OjR6OUi=
HCT-15 M4TIfWZ2dmO2aX;uJGF{e2G7 MnW3NVAuPTBizszN M2n0SFYuOzZiaB?= NEDFZZJqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MlzzNlUzOThyMki=
HT-29  NUexOmxpTnWwY4Tpc44hSXO|YYm= MlzSNVAuPTBizszN MWW2MVM3KGh? NYDJZXlOcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MWmyOVIyQDB{OB?=
HSC3  M2fqTGNmdGxiVnnhZoltcXS7IFHzd4F6 MnvBNQKBmzRyIN88US=> NUnIWWNvPDhiaB?= M{fqc2lEPTB;MkWuOeKyOS55OECg{txO MVGyOVE6QDd6OR?=
HSC3  M2TGdGFxd3C2b4Ppd{BCe3OjeR?= M1\wUlI2KM7:TR?= MUW0PEBp NH3Zb5JqdmS3Y3XzJIFxd3C2b4Ppdy=> MlfDNlUyQTh5OEm=
HSC3  MV;GeY5kfGmxbjDBd5NigQ>? MkDXNlUh|ryP NGPsbYw1QCCq NW\GVXFL\XiqaXLpeJMhe2mpbnnmbYNidnSueTDy[YR2[2WmIH3p[5JifGmxbjDjc41jcW6nZDD3bZRpKEOHVB?= MoP0NlUyQTh5OEm=
HSC3  MXnGeY5kfGmxbjDBd5NigQ>? NVe5b3RbOjVizszN MnnXOFghcA>? M{DIbYlvcGmkaYTzJGhUSzNiY3XscEBqdn[jc3nvckBkd22kaX7l[EB4cXSqIFPFWC=> MU[yOVE6QDd6OR?=
HSC3  MVXGeY5kfGmxbjDBd5NigQ>? MnPLNlUh|ryP NXvnW2R[PzJiaB?= M{S2fYRm[3KnYYPld{BOVVBvMjDhcoQhVU2SLUmgdJJwfGWrboRCpC=> M3roVFI2OTl6N{i5
201T  M1rLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX0TmI4OiCq MYfEUXNQ M37PcWlEPTB;NEiuOkDDvU1? M{XTUFI2ODV5OUSx
273T M3LiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy3NkBp NHnXRpFFVVOR NUXGNYt7UUN3ME24NE42KML3TR?= M1m0TlI2ODV5OUSx
Hep-2 NWLTdWtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLQN|AwPTBxMUCwJO69VQ>? NH[yd|cyOi9{ND:zOk81QCCq MV7EUXNQ MlrKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MX2yOFk6QDV4NB?=
Hep-2 MU\BdI9xfG:|aYOgRZN{[Xl? NF;6OVg2OCEQvF2= M3XKOFAuPDhiaB?= NEfHdoxFVVOR M4\SbIlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy MVuyOFk6QDV4NB?=
Hep-2 NILVOYlHfW6ldHnvckBCe3OjeR?= NInGfVE2OCEQvF2= MnniNE01QCCq MVTEUXNQ MlzCdoVlfWOnczD0bIUhfGWub33ldoF{\SCjY4Tpeol1gSCpcnHkeYFtdHl? Mkj2NlQ6QTh3NkS=
Hep-2 NHS2U3JHfW6ldHnvckBCe3OjeR?= NVTYR|htPTBizszN NIHIOlUxNTR6IHi= M1HTfWROW09? MYjk[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCqVFXSWC=> MYWyOFk6QDV4NB?=
SGC-7901 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLhT4EyOC93MD:xNFAh|ryP M2TVPVI1NzR6L{eyJIg> NYC3TVBKTE2VTx?= NHnIPHFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MoLyNlQ6QTJ7NUi=
MKN-45 M3SxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmruNVAwPTBxMUCwJO69VQ>? MVOyOE81QC95MjDo M1PWS2ROW09? NE\LVGZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MlvmNlQ6QTJ7NUi=
SGC-7901 NWLBdo5UTnWwY4Tpc44hSXO|YYm= NWmxXnV3OTBxNUCvNVAxKM7:TR?= M4\ZUFQ5KGh? M2\Qd2ROW09? MU\kc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NXTyZ|l3OjR7OUK5OVg>
MKN-45 NIPpO3hHfW6ldHnvckBCe3OjeR?= NFLtVHAyOC93MD:xNFAh|ryP MVm0PEBp NVr0b3VzTE2VTx?= MlrJ[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MWeyOFk6Ojl3OB?=
C666-1 MUfDfZRwfG:6aXPpeJkhSXO|YYm= NFrZ[pczOC16MDFOwG0> NIe3XWIzPCCq MXHk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg MXSyOFg2PDh|OB?=
CNE-1 NHzkcWlEgXSxdH;4bYNqfHliQYPzZZk> M{TKZ|IxNThyIN88US=> M1XKZVI1KGh? NGfMRYVl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh M2Dz[FI1QDV2OEO4
CNE-2 NWO3bVBVS3m2b4TvfIlkcXS7IFHzd4F6 NG\pfYwzOC16MDFOwG0> Ml3qNlQhcA>? NF3yRXFl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh MXmyOFg2PDh|OB?=
C666-1 MWTDfZRwfG:6aXPpeJkhSXO|YYm= MoL5OlAh|ryP NGnjVIM4KGR? MXrlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= NITK[okzPDh3NEizPC=>
CNE-1 NYTMSGJOS3m2b4TvfIlkcXS7IFHzd4F6 NYq3SmdIPjBizszN NHrm[Vg4KGR? Mnvx[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= MkXHNlQ5PTR6M{i=
SNU-1041 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfuOm82OC12MDFOwG0> NEf6Vm41QCCq MXPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Ml7aNlQ3QTJ5MEO=
SNU-1041 M2jUemZ2dmO2aX;uJGF{e2G7 MWSyNE8{OCEQvF2= M4ThfFQhcA>? NF;Ue21qdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>? NFLIfGszPDZ7MkewNy=>
SNU-1041 NGPsUWxHfW6ldHnvckBCe3OjeR?= NHrXZ2ExNTRyIN88US=> M4DkTVQhcA>? NXPQS4RJfXBvcnXneYxifGW|IFPIU3DDqGGodHXyJJRz\WG2bXXueEB4cXSqIHjp[4gh[2:wY3XueJJifGmxboO= M2W4OFI1Pjl{N{Cz
SGC-7901 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOwXnM2OC1zMkWg{txO NIOyU5kzPC92OD:3NkBp NVXCc3pjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MXKyOFY4PjN7NB?=
SGC-7901 NUPnc4hVSXCxcITvd4l{KEG|c3H5 NELaPZgyODBizszN NVS5XWtrPzJiaB?= Mm\kbY5lfWOnczDhdI9xfG:|aYO= NFPIXmQzPDZ5NkO5OC=>
SGC-7901 MnzYSpVv[3Srb36gRZN{[Xl? MUm3OU8yODBxMUK1JO69VQ>? MV:yOE81QC95MjDo MXLpcoNz\WG|ZYOgZ4F{eGG|ZT24JIFv\CBvOTDtVm5CKGW6cILld5Nqd25iaX6gZo91cCC2aX3lJIFv\CCmb4PlJI1idm6nch?= MUGyOFY4PjN7NB?=
LMeC  NEfIOY5HfW6ldHnvckBCe3OjeR?= NFfPT4EzOC93MDFOwG0> NVKyW3hNPDhiaB?= M3jaeoRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw NGq0T4IzPDZ3Nke0Oi=>
CMeC-1 NYnyRpFxS2WubDDWbYFjcWyrdImgRZN{[Xl? NYnWV5lMOjBxNUCg{txO MVy0PEBp M3m0ZolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{m0fVI1PjV4N{S2
LMeC MknCR4VtdCCYaXHibYxqfHliQYPzZZk> NIrkOnkzOC93MDFOwG0> MYe0PEBp M4[0b4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MVuyOFY2Pjd2Nh?=
CMeC-1 NFLWTHhHfW6ldHnvckBCe3OjeR?= MlTiNlAwPTBizszN MojiOFghcA>? MlvabY5lfWOnczDHNU1UKGG{cnXzeC=> MXOyOFY2Pjd2Nh?=
LMeC MV\GeY5kfGmxbjDBd5NigQ>? NI\hV3AzOC93MDFOwG0> NIPsWVQ1QCCq MnLSbY5lfWOnczDHNU1UKGG{cnXzeC=> MlLkNlQ3PTZ5NE[=
CMeC-1 MnfTSpVv[3Srb36gRZN{[Xl? MYmyNE82OCEQvF2= MnTXOFghcA>? NIOwcGxl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MkXINlQ3PTZ5NE[=
LMeC NH7ER2FHfW6ldHnvckBCe3OjeR?= MkjxNlAwPTBizszN MlfmOFghcA>? MVvk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1rGPVI1PjV4N{S2
CMeC-1 NF7lWFFHfW6ldHnvckBCe3OjeR?= NILoe4ozOC93MDFOwG0> MnfOOFghcA>? NH\0RY5qdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v M3XvVFI1PjV4N{S2
LMeC NFq1cXNHfW6ldHnvckBCe3OjeR?= MknXNlAwPTBizszN MnjCOFghcA>? MYHpcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u M3fFZVI1PjV4N{S2
OVCAR-3 NG\pPW9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV3kO3RxOTBiwsXN MlzJNUBp M1O1VYVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> M1X3XVI1PTJyMkK3
OVCAR-3 NYjCOmNsSXCxcITvd4l{KEG|c3H5 NG\RNpYyOCEEtV2= NVvWWHpROSCq M3exbJBzd22xdHXzJJBi[2yrdHH4[YwucW6mdXPl[EBieG:ydH;zbZPDqA>? MYiyOFUzODJ{Nx?=
OVCAR-3 M{DP[GZ2dmO2aX;uJGF{e2G7 MXSxNEDDvU1? NETtUWUyKGh? M2XoR4VvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg NXPxbpA4OjR3MkCyNlc>
OVCAR-3 NW\CfXFGTnWwY4Tpc44hSXO|YYm= NWHGNZhJOTBiwsXN Moi1NUBp NHftR2lld3ewLYLl[5Vt[XSnczDOSk3PwkJiYXP0bZZifGmxbjDpcoR2[2WmIHL5JJBi[2yrdHH4[Yw> NHrNTWczPDV{MEKyOy=>
OVCAR-3 Ml3nSpVv[3Srb36gRZN{[Xl? M1ywRVExKML3TR?= NXOzTpZkOSCq NGn5VZBqdmirYnn0d{Bx[WOuaYThfIVtNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MkXTNlQ2OjB{Mke=
CF33 MVvGeY5kfGmxbjDBd5NigQ>? NFu4VlEyODBizszN NH\FS|IzPCCq NVPn[3cycW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMjDwdo91\WmwIHX4dJJme3Orb36= MnzNNlQ2ODN5OEK=
CF33 NFvoZ2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfJeIxDOTBvMUCwJO69VQ>? MojQNE01KGR? M2jnV4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmLPNlQ2ODN5OEK=
CF33 NFTMV|NHfW6ldHnvckBCe3OjeR?= NYXUZo4yOTBvMUCwJO69VQ>? M33rd|QuOjRiaB?= NX\4b2hK\GWlcnXhd4V{KGOnbHzzJIlvKHSqZTDTJJBp[XOnIHHu[EBqdmO{ZXHz[ZMh[2WubIOgbY4hTzBxR{GgZZJz\XO2 MUKyOFUxOzd6Mh?=
LNCaP M3P4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn5Sm4zNzVxMUCg{txO MV[5OkBp NVTLbXNUcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NVzVUpVOOjR{OU[5O|g>
LNCaP MWDBdI9xfG:|aYOgRZN{[Xl? NYm1XVE4Oi93L{GwJO69VQ>? Mlf3PVYhcA>? NVTPbW5tcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDheI9zfmG|dHH0bY4> NFvVS4wzPDJ7Nkm3PC=>
PC-3  NGr1ZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlThNE02OCEQvF2= MWK0PQKBkWh? NVPkfGdTcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MYiyOFEzPzh6Mh?=
PC-3  NGi4eINE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mn7MNE0yODBizszN NYjUeZoyPzJiaB?= NGTidJVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MlSzNlQyOjd6OEK=

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water slightly soluble or insoluble
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID